Is Insmed Incorporated (INSM) a Buy, Sell, or Hold?
NASDAQ : INSM
Insmed Incorporated
$106.92 USD
-$0.49 (-0.46%)
- Volume
- 1.91M
- Average Volume
- 3.86M
- Market Capitalization
- $23.18B
- P/E Ratio
- -18.59
- Dividend Yield
- 0.00%
- Price Target
- $200.00
- Year High
- $212.75
- Year Low
- $90.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.47
Company Overview
NASDAQ
William H. Lewis
Biotechnology
Healthcare
INSM
1664
US
USD
Liquidity Metrics
1.06
4.47
4.10
1.61
0.00
Sales & Valuation
$606.42M
28.28
32.68
-24.35
-4.42
Profitability
-$6.41
-$1.28B
-144.44%
-143.76%
-130.11%
-57.02%
P/E Metrics
-18.59
-13.63
-13.63
Analyst Price Target & Rating
$200.00
$231.00
$161.00
1/5
35 Analysts
-46.54%
Financial Health Scores
5.60
4/9
$1.25B
$2.08B
$1.37B
-$1.1B
Key Metrics (TTM)
$23.34B
28.48
-21.59
4.47
-130.11%
-65.28%
-5.14%
-4.11%
223 days
Company Executives
| Name | Title |
|---|---|
| Bryan Dunn | Vice President of Investor Relations |
| Martina Flammer | Chief Medical Officer |
| Brian K. Kaspar | Chief Scientific Officer |
| Michael Alexander Smith | Chief Legal Officer & Corporate Secretary |
| Christie Camelio | Chief Compliance Officer |
| Sara Bonstein | Chief Financial Officer |
| Claire Mulhearn | Vice President of Corporate Communications |
| Roger Adsett | Chief Operating Officer |
| William H. Lewis | President, Chief Executive Officer & Chairman |
| S. Nicole Schaeffer | Chief People Strategy Officer |
Poll Results
No votes yet today — be the first to share your view!
About Insmed Incorporated (NASDAQ:INSM) Stock
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arte ... rial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
2026-07-23 07:00:00
BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.
Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSM
2026-07-22 04:03:17
Andra AP fonden lifted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 114.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,970 shares of the biopharmaceutical company's stock after acquiring an additional 41,670 shares during the
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
2026-07-21 07:58:34
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
2026-07-21 07:41:44
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.
Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?
2026-07-20 11:36:41
Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biotech names on wildly different trajectories, the one semiconductor stock nobody can ignore, and an Argentine oil producer sitting on a shale reserve about to unlock its first export pipeline.
Bank of New York Mellon Corp Cuts Stake in Insmed, Inc. $INSM
2026-07-19 04:27:36
Bank of New York Mellon Corp lessened its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 9.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,262,749 shares of the biopharmaceutical company's stock after selling 127,293 shares
2026-07-16 16:26:35
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
2026-07-16 14:32:08
Insmed Incorporated (NASDAQ:INSM) on Thursday reported 12-month results from the ongoing open-label extension (OLE) study of its once-daily treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) patients.
Frequently Asked Questions
-
What is the current Insmed Incorporated (INSM) stock price?
-
Insmed Incorporated(NASDAQ:INSM) stock price is $106.92 in the last trading session. During the trading session, INSM stock reached the peak price of $212.75 while $90.39 was the lowest point it dropped to. The percentage change in INSM stock occurred in the recent session was --0.46% while the dollar amount for the price change in INSM stock was -$0.49.
-
INSM's industry and sector of operation?
-
The NASDAQ listed INSM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INSM?
-
Bryan Dunn | Vice President of Investor Relations
Martina Flammer | Chief Medical Officer
Brian K. Kaspar | Chief Scientific Officer
Michael Alexander Smith | Chief Legal Officer & Corporate Secretary
Christie Camelio | Chief Compliance Officer -
How many employees does INSM have?
-
Number of INSM employees currently stands at 1664. INSM operates from 700 US Highway 202/206, Bridgewater, NJ 08807, US.
-
Link for INSM official website?
-
Official Website of INSM is: https://www.insmed.com
-
How do I contact INSM?
-
INSM could be contacted at phone #908 977 9900 and can also be accessed through its website. INSM operates from 700 US Highway 202/206, Bridgewater, NJ 08807, US.
-
How many shares of INSM are traded daily?
-
The average number of INSM shares traded daily for last 3 months was 3.86M.
-
What is the market cap of INSM currently?
-
The market value of INSM currently stands at $23.18B with its latest stock price at $106.92